Next Article in Journal
The Value of Contrast-Enhanced Ultrasound (CEUS) in the Detection of Perfusion Disturbances in Abdominal Wall Hernias Compared with Surgical and Histological Assessment
Previous Article in Journal
Identification of MicroRNAs as Potential Blood-Based Biomarkers for Diagnosis and Therapeutic Monitoring of Active Tuberculosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 12
Issue 2
10.3390/diagnostics12020366
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer

by
Ilias Nikas
1,2,
Constantinos Giaginis
3,
Kalliopi Petrouska
1,
Paraskevi Alexandrou
1,
Artemis Michail
4,
Panagiotis Sarantis
1,
Gerasimos Tsourouflis
5,
Eugene Danas
1,
Alexandros Pergaris
1,
Panagiotis K. Politis
4,
Lydia Nakopoulou
1 and
Stamatios Theocharis
1,*
1
First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece
2
School of Medicine, European University Cyprus, Nicosia 2404, Cyprus
3
Department of Food Science and Nutrition, School of Environment, University of Aegean, Myrina, 811 00 Lemnos, Greece
4
Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Efesiou Str., 115 27 Athens, Greece
5
Second Department of Propedeutic Surgery, Laikon Hospital, Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece
*
Author to whom correspondence should be addressed.
Diagnostics 2022, 12(2), 366; https://doi.org/10.3390/diagnostics12020366
Submission received: 18 December 2021 / Revised: 21 January 2022 / Accepted: 28 January 2022 / Published: 1 February 2022
(This article belongs to the Section Pathology and Molecular Diagnostics)
Browse Figures
Versions Notes

Abstract

Ongoing research continues to elucidate the complex role of ephrin receptors (EPHs) and their ligands (ephrins) in breast cancer pathogenesis, with their varying expression patterns implied to have an important impact on patients’ outcome. The current study aims to investigate the clinical significance of EPHA2, EPHA4, and EPHA7 expression in triple-negative breast cancer (TNBC) cases. EPHA2, EPHA4, and EPHA7 protein expression was assessed immunohistochemically on formalin-fixed and paraffin-embedded (FFPE) TNBC tissue sections from 52 TNBC patients and correlated with key clinicopathologic parameters and patients’ survival data (overall survival (OS); disease-free survival (DFS)). EPHA2, EPHA4, and EPHA7 expression was further examined in TNBC cell lines. EPHA2 overexpression was observed in 26 (50%) of the TNBC cases, who exhibited a shorter OS and DFS than their low-expression counterparts, with EPHA2 representing an independent prognostic factor for OS and DFS (p = 0.0041 and p = 0.0232, respectively). EPHA4 overexpression was associated with lymph node metastasis in TNBC patients (p = 0.0546). Alterations in EPHA2, EPHA4, and EPHA7 expression levels were also noted in the examined TNBC cell lines. Our study stresses that EPHA2 expression constitutes a potential prognostic factor for TNBC patients. Given the limited treatment options and poorer outcome that accompany the TNBC subtype, EPHA2 could also pose as a target for novel, more personalized, and effective therapeutic approaches for those patients.
Keywords: biomarker; basal-like breast cancer; EPH; ephrin; targeted therapy biomarker; basal-like breast cancer; EPH; ephrin; targeted therapy

Share and Cite

MDPI and ACS Style

Nikas, I.; Giaginis, C.; Petrouska, K.; Alexandrou, P.; Michail, A.; Sarantis, P.; Tsourouflis, G.; Danas, E.; Pergaris, A.; Politis, P.K.; et al. EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer. Diagnostics 2022, 12, 366. https://doi.org/10.3390/diagnostics12020366

AMA Style

Nikas I, Giaginis C, Petrouska K, Alexandrou P, Michail A, Sarantis P, Tsourouflis G, Danas E, Pergaris A, Politis PK, et al. EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer. Diagnostics. 2022; 12(2):366. https://doi.org/10.3390/diagnostics12020366

Chicago/Turabian Style

Nikas, Ilias, Constantinos Giaginis, Kalliopi Petrouska, Paraskevi Alexandrou, Artemis Michail, Panagiotis Sarantis, Gerasimos Tsourouflis, Eugene Danas, Alexandros Pergaris, Panagiotis K. Politis, and et al. 2022. "EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer" Diagnostics 12, no. 2: 366. https://doi.org/10.3390/diagnostics12020366

APA Style

Nikas, I., Giaginis, C., Petrouska, K., Alexandrou, P., Michail, A., Sarantis, P., Tsourouflis, G., Danas, E., Pergaris, A., Politis, P. K., Nakopoulou, L., & Theocharis, S. (2022). EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer. Diagnostics, 12(2), 366. https://doi.org/10.3390/diagnostics12020366

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop